Kura Oncology (NASDAQ:KURA) stock slid 17% post-market after the company announced a collaboration deal with Japan's Kyowa Kirin (OTCPK:KNBWY) for its leukemia drug candidate ziftomenib worth up ...

Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies said Wednesday. Kyowa ...

Anarchist. Pessimist. Bipolar. Hacker. Hyperpolyglot. Musician. Ex-(semi-)pro gamer. They/Them. Senior engineer building an A/V CDN for a living.

Japan-based Kyowa Kirin is fronting $330 million and pledging up to $1.1 billion in milestones to split the U.S. profits of Kura Oncology’s phase 2-stage oral leukemia treatment as well as to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Today, some squiddy drug delivery, a leukemia deal between Kura ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Kura Oncology announced on Wednesday that it will collaborate with Japan’s Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib. According to the company’s statement ...

The FDA recently approved the first drug in a new class of leukemia medicines. Kura Oncology’s endeavor to follow that newly blazed regulatory trail is now infused with $330 million from a ...